# Senisca

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/senisca

- Industry: Biotechnology
- Headquarters: Exeter, UK
- Website: www.senisca.com
- Total disclosed funding: $7.5M
- Latest round: Seed (Feb 20, 2024)
- Investors on record: 7

## About

Based in the UK, and founded in 2020 by CSO, Professor Lorna Harries, CTO, Ben Lee, and CEO, Kirsty Semple, Senisca Ltd, formed as a spinout company from the University of Exeter, operates as a provider of a new generation of senotherapeutic procedures to treat the diseases and aesthetic signs of ageing. In June 2021, Senisca raised GBP 1.82 million in seed funding from Apex Ventures with participation from QantX, Emerging Longevity Ventures, Longevity Tech Fund, R42, and Trend Investment Group.

The company offers oligonucleotide-based therapeutic solutions used for the treatment of age-related diseases, helping reduce disease incidence and severity. The company is working on druggable means to reverse senescence through the modulation of RNA splicing.

The company plans to use the June 2021 funding to expand its management team and advance its antiaging chemicals to the next level of ex vivo laboratory studies.

## Funding rounds

- Seed, Feb 20, 2024, $4.7M — Apex Ventures, Trend Investment Group, Emerging Longevity Ventures, R42, QantX, LifeSpan Vision Ventures
- Seed, Apr 5, 2022, $2.8M — Apex Ventures, Trend Investment Group, Emerging Longevity Ventures, Longevity Tech Fund, R42, QantX

## Investors

- Apex Ventures (https://capitalatlas.ai/funds/apex-ventures) — Seed
- Trend Investment Group (https://capitalatlas.ai/funds/trend-investment-group) — Seed
- Emerging Longevity Ventures — Seed
- Longevity Tech Fund (https://capitalatlas.ai/funds/longevity-tech-fund) — Seed
- R42 (https://capitalatlas.ai/funds/r42) — Seed
- QantX (https://capitalatlas.ai/funds/qantx) — Seed
- LifeSpan Vision Ventures (https://capitalatlas.ai/funds/lifespan-vision-ventures) — Seed